In BRAF V600E melanomas, loss of NF1, frequently co-occurring with BRAF and RAS alterations, allows a high level of activity of RAS-GTP and resistance to BRAF inhibitors (Nissan et al., 2014). Here, BRAF is linked to melanoma.